{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:56:08Z","timestamp":1789916168409,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005874","name":"Universit\u00e0 degli Studi G. D'Annunzio Chieti Pescara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005874","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Case-reports\/series and cohorts of Guillain\u2013Barr\u00e9 syndrome (GBS) associated with COVID-19 vaccination have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of cohort studies of GBS after COVID-19 vaccination was carried out. Incidence and incidence rate ratio for a number of vaccine doses and risk of GBS, also considering the specific vaccine technology, were calculated in a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 554 citations retrieved, 518 were discarded as irrelevant. We finally included 15 studies. The random effect model yielded, regardless of the vaccine technology, 1.25 (95%CI 0.21; 2.83) GBS cases per million of COVID-19 vaccine doses, 3.93 (2.54; 5.54) cases per million doses for adenovirus-vectored vaccines and 0.69 (0.38; 1.06) cases per million doses for mRNA vaccines. The GBS risk was 2.6 times increased with the first dose. Regardless of the vaccine technology, the GBS risk was not increased but disaggregating the data it was 2.37 (1.67; 3.36) times increased for adenovirus-vectored vaccines and 0.32 (0.23; 0.47) for mRNA vaccines. Mortality for GBS after vaccination was 0.10 per million doses and 4.6 per GBS cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adenovirus-vectored vaccines showed a 2.4 times increased risk of GBS that was about seven times higher compared with mRNA-based vaccines. The decreased GBS risk associated with mRNA vaccines was possibly due to an elicited reduction of infections, including SARS-CoV-2, associated with GBS during the vaccination period. How adenovirus-vectored COVID-19 vaccines may trigger GBS is unclear and further studies should investigate the relationship between vaccine technologies and GBS risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-024-12186-7","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:41:18Z","timestamp":1705495278000},"page":"1063-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Guillain\u2013Barr\u00e9 syndrome and COVID-19 vaccination: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"271","author":[{"given":"Stefano","family":"Censi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Bisaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8131-8912","authenticated-orcid":false,"given":"Antonino","family":"Uncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"12186_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FA et al (2019) Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps. Nat Rev Neurol 15:671\u2013683","journal-title":"Nat Rev Neurol"},{"key":"12186_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan A, Madle GC, Seaman HE, De Vries CS (2009) The epidemiology of Guillain\u2013Barr\u00e9 syndrome worldwide. Neuroepidemiology 32:150\u2013163. https:\/\/doi.org\/10.1159\/000184748","journal-title":"Neuroepidemiology"},{"key":"12186_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"the GBS Classification Group, Wakerley BR, Uncini A, Yuki N (2014) Guillain\u2013Barr\u00e9 and Miller Fisher syndromes\u2014new diagnostic classification. Nat Rev Neurol 10:537\u2013544. https:\/\/doi.org\/10.1038\/nrneurol.2014.138","journal-title":"Nat Rev Neurol"},{"key":"12186_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","volume":"119","author":"AD Langmuir","year":"1984","unstructured":"Langmuir AD, Bregman DJ, Kurland LT et al (1984) An epidemiologic and clinical evaluation of Guillain\u2013Barr\u00e9 syndrome reported in association with the administration of Swine influenza vaccines. Am J Epidemiol 119:841\u2013879. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a113809","journal-title":"Am J Epidemiol"},{"key":"12186_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al (1979) Guillain\u2013Barre syndrome following vaccination in the national influenza immunization program, United States, 1976\u201319771. Am J Epidemiol 110:105\u2013123. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a112795","journal-title":"Am J Epidemiol"},{"key":"12186_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","volume":"339","author":"T Lasky","year":"1998","unstructured":"Lasky T, Terracciano GJ, Magder L et al (1998) The Guillain\u2013Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines. N Engl J Med 339:1797\u20131802. https:\/\/doi.org\/10.1056\/NEJM199812173392501","journal-title":"N Engl J Med"},{"key":"12186_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","volume":"166","author":"DN Juurlink","year":"2006","unstructured":"Juurlink DN (2006) Guillain\u2013Barr\u00e9 syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 166:2217. https:\/\/doi.org\/10.1001\/archinte.166.20.2217","journal-title":"Arch Intern Med"},{"key":"12186_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","volume":"181","author":"R Goud","year":"2021","unstructured":"Goud R, Lufkin B, Duffy J et al (2021) Risk of Guillain\u2013Barr\u00e9 syndrome following recombinant Zoster vaccine in medicare beneficiaries. JAMA Intern Med 181:1623. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6227","journal-title":"JAMA Intern Med"},{"key":"12186_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cit222","volume":"57","author":"R Baxter","year":"2013","unstructured":"Baxter R, Bakshi N, Fireman B et al (2013) Lack of association of Guillain\u2013Barre syndrome with vaccinations. Clin Infect Dis 57:197\u2013204. https:\/\/doi.org\/10.1093\/cid\/cit222","journal-title":"Clin Infect Dis"},{"key":"12186_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C et al (2021) Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 385:585\u2013594. https:\/\/doi.org\/10.1056\/NEJMoa2108891","journal-title":"N Engl J Med"},{"key":"12186_CR11","doi-asserted-by":"publisher","first-page":"JC15","DOI":"10.7326\/ACPJ202102160-015","volume":"174","author":"Z Chagla","year":"2021","unstructured":"Chagla Z (2021) The BNT162b2 (BioNTech\/Pfizer) vaccine had 95% efficacy against COVID-19 \u22657 days after the 2nd dose. Ann Intern Med 174:JC15. https:\/\/doi.org\/10.7326\/ACPJ202102160-015","journal-title":"Ann Intern Med"},{"key":"12186_CR12","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E et al (2021) BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384:1412\u20131423. https:\/\/doi.org\/10.1056\/NEJMoa2101765","journal-title":"N Engl J Med"},{"key":"12186_CR13","unstructured":"EMA (2021) EMA 14 July 2021 COVID-19 vaccine safety update: VAXZEVRIA AstraZeneca AB"},{"key":"12186_CR14","doi-asserted-by":"publisher","unstructured":"Rosenblum HG, Hadler SC, Moulia D, et al (2021) Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization Practices\u2014United States, July 2021. MMWR Morb Mortal Wkly Rep 70: 1094\u20131099. https:\/\/doi.org\/10.15585\/mmwr.mm7032e4","DOI":"10.15585\/mmwr.mm7032e4"},{"key":"12186_CR15","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone M, Handunnetthi L, Saatci D et al (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 27:2144\u20132153. https:\/\/doi.org\/10.1038\/s41591-021-01556-7","journal-title":"Nat Med"},{"key":"12186_CR16","unstructured":"Our World in Data Our World in Data-COVID19 vaccination worldwide"},{"key":"12186_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","volume":"381","author":"DA Salmon","year":"2013","unstructured":"Salmon DA, Proschan M, Forshee R et al (2013) Association between Guillain\u2013Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. The Lancet 381:1461\u20131468. https:\/\/doi.org\/10.1016\/S0140-6736(12)62189-8","journal-title":"The Lancet"},{"key":"12186_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 62:1006\u20131012. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005","journal-title":"J Clin Epidemiol"},{"key":"12186_CR19","unstructured":"Wells G, Shea B, O\u2019Connell D, et al The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"12186_CR20","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with R: a hands-on guide. Chapman and Hall\/CRC, New York"},{"key":"12186_CR21","first-page":"1","volume":"47","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen D, Wang Y, Han Y (2022) Using Freeman\u2013Tukey double arcsine transformation in meta-analysis of single proportions. Aesthetic Plast Surg 47:1\u20132","journal-title":"Aesthetic Plast Surg"},{"key":"12186_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statist Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Statist Med"},{"key":"12186_CR23","doi-asserted-by":"publisher","first-page":"e13524","DOI":"10.1111\/eci.13524","volume":"51","author":"FM Al Amer","year":"2021","unstructured":"Al Amer FM, Lin L (2021) Empirical assessment of prediction intervals in Cochrane meta-analyses. Eur J Clin Investig 51:e13524. https:\/\/doi.org\/10.1111\/eci.13524","journal-title":"Eur J Clin Investig"},{"key":"12186_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.295.6.676","volume":"295","author":"JL Peters","year":"2006","unstructured":"Peters JL (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676. https:\/\/doi.org\/10.1001\/jama.295.6.676","journal-title":"JAMA"},{"key":"12186_CR25","doi-asserted-by":"publisher","first-page":"e2253845","DOI":"10.1001\/jamanetworkopen.2022.53845","volume":"6","author":"WE Abara","year":"2023","unstructured":"Abara WE, Gee J, Marquez P et al (2023) Reports of Guillain\u2013Barr\u00e9 syndrome after COVID-19 vaccination in the United States. JAMA Netw Open 6:e2253845. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.53845","journal-title":"JAMA Netw Open"},{"key":"12186_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40261-022-01191-1","volume":"42","author":"DH Abdel-Qader","year":"2022","unstructured":"Abdel-Qader DH, Abdel-Qader H, Silverthorne J et al (2022) Active safety surveillance of four types of COVID-19 vaccines: a national study from Jordan. Clin Drug Investig 42:813\u2013827. https:\/\/doi.org\/10.1007\/s40261-022-01191-1","journal-title":"Clin Drug Investig"},{"key":"12186_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","volume":"42","author":"M Atzenhoffer","year":"2022","unstructured":"Atzenhoffer M, Auffret M, Pegat A et al (2022) Guillain\u2013Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data. Clin Drug Investig 42:581\u2013592. https:\/\/doi.org\/10.1007\/s40261-022-01164-4","journal-title":"Clin Drug Investig"},{"key":"12186_CR28","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/ene.15504","volume":"29","author":"M Garc\u00eda-Grimshaw","year":"2022","unstructured":"Garc\u00eda-Grimshaw M, Galnares-Olalde JA, Bello-Chavolla OY et al (2022) Incidence of Guillain\u2013Barr\u00e9 syndrome following SARS-CoV -2 immunization: analysis of a nationwide registry of recipients of 81 million doses of seven vaccines. Eur J Neurol 29:3368\u20133379. https:\/\/doi.org\/10.1111\/ene.15504","journal-title":"Eur J Neurol"},{"key":"12186_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbi.2020.05.051","volume":"87","author":"A Gupta","year":"2020","unstructured":"Gupta A, Paliwal VK, Garg RK (2020) Is COVID-19-related Guillain\u2013Barr\u00e9 syndrome different? Brain Behav Immun 87:177\u2013178. https:\/\/doi.org\/10.1016\/j.bbi.2020.05.051","journal-title":"Brain Behav Immun"},{"key":"12186_CR30","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/s41598-023-30940-1","volume":"13","author":"J Ha","year":"2023","unstructured":"Ha J, Park S, Kang H et al (2023) Real-world data on the incidence and risk of Guillain\u2013Barr\u00e9 syndrome following SARS-CoV-2 vaccination: a prospective surveillance study. Sci Rep 13:3773. https:\/\/doi.org\/10.1038\/s41598-023-30940-1","journal-title":"Sci Rep"},{"key":"12186_CR31","doi-asserted-by":"publisher","first-page":"120030","DOI":"10.1016\/j.jns.2021.120030","volume":"430","author":"JS Koh","year":"2021","unstructured":"Koh JS, Hoe RHM, Yong MH et al (2021) Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. J Neurol Sci 430:120030. https:\/\/doi.org\/10.1016\/j.jns.2021.120030","journal-title":"J Neurol Sci"},{"key":"12186_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068373","author":"X Li","year":"2022","unstructured":"Li X, Ravent\u00f3s B, Roel E et al (2022) Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. https:\/\/doi.org\/10.1136\/bmj-2021-068373","journal-title":"BMJ"},{"key":"12186_CR33","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1016\/j.vaccine.2022.10.084","volume":"40","author":"J Osowicki","year":"2022","unstructured":"Osowicki J, Morgan HJ, Harris A et al (2022) Guillain\u2013Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Australia. Vaccine 40:7579\u20137585. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.084","journal-title":"Vaccine"},{"key":"12186_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14740338.2022.2120607","volume":"22","author":"M Otero-Losada","year":"2023","unstructured":"Otero-Losada M, Petrovsky N, Alami A et al (2023) Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom. Expert Opin Drug Saf 22:343\u2013349. https:\/\/doi.org\/10.1080\/14740338.2022.2120607","journal-title":"Expert Opin Drug Saf"},{"key":"12186_CR35","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3201\/eid2712.211634","volume":"27","author":"S-C Shao","year":"2021","unstructured":"Shao S-C, Wang C-H, Chang K-C et al (2021) Guillain\u2013Barr\u00e9 syndrome associated with COVID-19 vaccination. Emerg Infect Dis 27:3175\u20133178. https:\/\/doi.org\/10.3201\/eid2712.211634","journal-title":"Emerg Infect Dis"},{"key":"12186_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","volume":"28","author":"D Shasha","year":"2022","unstructured":"Shasha D, Bareket R, Sikron FH et al (2022) Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. Clin Microbiol Infect 28:130\u2013134. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.018","journal-title":"Clin Microbiol Infect"},{"key":"12186_CR37","doi-asserted-by":"publisher","first-page":"1004024","DOI":"10.1371\/journal.pmed.1004024","volume":"19","author":"S Takuva","year":"2022","unstructured":"Takuva S, Takalani A, Seocharan I et al (2022) Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa A phase 3b implementation trial. PLoS Med 19:1004024. https:\/\/doi.org\/10.1371\/journal.pmed.1004024","journal-title":"PLoS Med"},{"key":"12186_CR38","doi-asserted-by":"publisher","first-page":"e000309","DOI":"10.1136\/bmjno-2022-000309","volume":"4","author":"AA Tamborska","year":"2022","unstructured":"Tamborska AA, Singh B, Leonhard SE et al (2022) Guillain\u2013Barr\u00e9 syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. BMJ Neurol Open 4:e000309. https:\/\/doi.org\/10.1136\/bmjno-2022-000309","journal-title":"BMJ Neurol Open"},{"key":"12186_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/brain\/awac067","volume":"146","author":"RYS Keh","year":"2023","unstructured":"Keh RYS, Scanlon S, Datta-Nemdharry P et al (2023) COVID-19 vaccination and Guillain\u2013Barr\u00e9 syndrome: analyses using the National Immunoglobulin Database. Brain 146:739\u2013748. https:\/\/doi.org\/10.1093\/brain\/awac067","journal-title":"Brain"},{"key":"12186_CR40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs BC, Rothbarth PH, Van Der Mech\u00e9 FGA et al (1998) The spectrum of antecedent infections in Guillain\u2013Barr\u00e9 syndrome: a case\u2013control study. Neurology 51:1110\u20131115. https:\/\/doi.org\/10.1212\/WNL.51.4.1110","journal-title":"Neurology"},{"key":"12186_CR41","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1016\/j.vaccine.2019.08.087","volume":"37","author":"MM McNeil","year":"2019","unstructured":"McNeil MM, Paradowska-Stankiewicz I, Miller ER et al (2019) Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the vaccine adverse event reporting System (VAERS), United States, October 2011\u2013July 2018. Vaccine 37:6760\u20136767. https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.087","journal-title":"Vaccine"},{"key":"12186_CR42","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1093\/cid\/ciaa1682","volume":"72","author":"K Huh","year":"2021","unstructured":"Huh K, Jung J, Hong J et al (2021) Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) Outbreak in Korea: A Nationwide Surveillance Study. Clin Infect Dis 72:e184\u2013e191. https:\/\/doi.org\/10.1093\/cid\/ciaa1682","journal-title":"Clin Infect Dis"},{"key":"12186_CR43","doi-asserted-by":"publisher","first-page":"e000378","DOI":"10.1136\/bmjno-2022-000378","volume":"4","author":"H Lee","year":"2022","unstructured":"Lee H, Heo N, Kwon D, Ha J (2022) Deciphering changes in the incidence of the Guillain\u2013Barr\u00e9 syndrome during the COVID-19 pandemic: a nationwide time-series correlation study. BMJ Neurol Open 4:e000378. https:\/\/doi.org\/10.1136\/bmjno-2022-000378","journal-title":"BMJ Neurol Open"},{"key":"12186_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16094","author":"S Censi","year":"2023","unstructured":"Censi S, Bisaccia G, Gallina S et al (2023) Guillain\u2212Barr\u00e9 syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the \u2018Italian factor.\u2019 Eur J Neurol Ene. https:\/\/doi.org\/10.1111\/ene.16094","journal-title":"Eur J Neurol Ene"},{"key":"12186_CR45","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1111\/ene.14860","volume":"28","author":"L Palaiodimou","year":"2021","unstructured":"Palaiodimou L, Stefanou M-I, Katsanos AH et al (2021) Prevalence, clinical characteristics and outcomes of Guillain\u2013Barr\u00e9 syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol 28:3517\u20133529","journal-title":"Eur J Neurol"},{"key":"12186_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207900","author":"H Bishara","year":"2023","unstructured":"Bishara H, Arbel A, Barnett-Griness O, Bloch S, Cohen S, Najjar-Debbiny R et al (2023) Association between Guillain\u2013Barr\u00e9 syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207900","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12186-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T03:09:19Z","timestamp":1708916959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12186-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["12186"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12186-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}